Cytokine based immunotherapies included interferon-alpha [12] and high dose interleukin 2 (IL-2) [13], while mTOR inhibitors approved for RCC treatment are everolimus [14] and temsirolimus [15]. The gene discussed is MTOR; the disease is renal cell carcinoma.